William Allan Corp Sells 64 Shares of Stryker Co. (NYSE:SYK)

William Allan Corp lowered its position in Stryker Co. (NYSE:SYK) by 2.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,855 shares of the medical technology company’s stock after selling 64 shares during the period. William Allan Corp’s holdings in Stryker were worth $1,032,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of SYK. Wealth Enhancement Advisory Services LLC grew its position in shares of Stryker by 78.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock worth $45,260,000 after purchasing an additional 58,673 shares in the last quarter. OFI Invest Asset Management raised its position in shares of Stryker by 3,210.9% during the second quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company’s stock valued at $1,062,000 after buying an additional 3,243 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Stryker by 2.7% in the second quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company’s stock worth $210,289,000 after buying an additional 16,504 shares in the last quarter. Sivik Global Healthcare LLC boosted its position in shares of Stryker by 8.0% during the third quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock worth $9,754,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Fiera Capital Corp grew its stake in Stryker by 42.1% during the second quarter. Fiera Capital Corp now owns 16,713 shares of the medical technology company’s stock valued at $5,687,000 after acquiring an additional 4,948 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.4 %

SYK opened at $388.14 on Friday. Stryker Co. has a one year low of $285.79 and a one year high of $398.20. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The stock has a market cap of $147.97 billion, a price-to-earnings ratio of 41.60, a P/E/G ratio of 2.93 and a beta of 0.91. The stock’s 50 day moving average price is $367.97 and its 200-day moving average price is $350.94.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business’s revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the firm posted $2.46 earnings per share. On average, equities analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on SYK shares. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. BTIG Research boosted their target price on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group raised their price target on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Citigroup upped their price objective on Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Piper Sandler reissued an “overweight” rating and issued a $420.00 target price (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $393.65.

Insider Activity at Stryker

In other news, VP M Kathryn Fink sold 2,121 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00. Following the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,715,540. This trade represents a 17.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 66,781 shares of company stock worth $24,612,275 in the last 90 days. 5.90% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.